AP NEWS
Press release content from Business Wire. The AP news staff was not involved in its creation.
PRESS RELEASE: Paid content from Business Wire
Press release content from Business Wire. The AP news staff was not involved in its creation.

Global Ibrance Drug Insights Report 2019-2021: MOA, Target, Dosage, Route of Administration, Molecule Type, Strength, Chemical type and ATC Classification - ResearchAndMarkets.com

November 11, 2019 GMT

DUBLIN--(BUSINESS WIRE)--Nov 11, 2019--

The “Ibrance - Drug Insight, 2019” report has been added to ResearchAndMarkets.com’s offering.

“Ibrance Drug Insight, 2019” highlights the drug marketed details and the Global API Manufacturers details across the globe along with their location.

The report covers the Global Market Assessment of the Ibrance covering the historical global sales and also provides the Ibrance sales estimation during the forecasted period (2019-2021). The report also covers the patents information and market exclusivity data, route of synthesis, market competition, and API manufacturers by country.

In addition to this, the report also provides the SWOT analysis for Ibrance and emerging therapies in this space.

Scope

Reasons to Buy

Key Topics Covered:

1. Report Introduction

2. Ibrance - Overview

3. Product Details

4. Ibrance Sales Assessment

5. Patent Details

6. Global API Manufacturers Assessment

7. Market Competition

8. Emerging Therapies

9. SWOT Analysis

For more information about this report visit https://www.researchandmarkets.com/r/52y9zn

View source version on businesswire.com:https://www.businesswire.com/news/home/20191111005257/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

KEYWORD:

INDUSTRY KEYWORD: HEALTH PHARMACEUTICAL

SOURCE: Research and Markets

Copyright Business Wire 2019.

PUB: 11/11/2019 06:11 AM/DISC: 11/11/2019 06:11 AM

http://www.businesswire.com/news/home/20191111005257/en